Skip to main content

Table 3 Workstreams Not Prioritized at this Stage

From: CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives

Workstream Reason for not prioritizing at this stage
Novel combinations Would first require the identification and development of new chemotypes from which to design appropriate novel combinations
Natural products Considered an important route to identifying new drugs but would require broader discussion with experts specializing in this field than is possible in the first phase of the work of CRIMALDDI.
Novel drugs for severe malaria Need appropriate models to study. Also likely that a first step would be to identify novel chemotypes and then compounds with the appropriate PK/PD properties for severe malaria.
Novel drugs for malaria in pregnancy Need appropriate models to study. Also likely that a first step would be to identify novel chemotypes and then compounds with the appropriate PK/PD properties for malaria in pregnancy.
Drugs for mass administration Starting point would be novel chemotypes from which drugs with appropriate efficacy & safety profiles can be identified.
Drugs to overcome resistance mechanisms (non-artemisinin) The development of novel chemotypes would, by definition, identify molecular frameworks that could overcome resistance by different mechanisms. A specific effort to find molecules of the same class to overcome resistance would not be the most productive way forward.
  1. These equally important workstreams were not included in this phase of the project for the reasons explained in the table. However, the Consortium or others may address them in the future.